Prevalence of type-1 interferon autoantibodies in adults with non-COVID-19 acute respiratory failure

Respiratory Research - Tập 23 - Trang 1-4 - 2022
Rajani Ghale1,2,3, Natasha Spottiswoode2,3, Mark S. Anderson3,4, Anthea Mitchell5, Grace Wang5, Carolyn S. Calfee1,3, Joseph L. DeRisi5,6, Charles R. Langelier2,3,6
1Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, University of California, San Francisco, USA
2Division of Infectious Diseases, University of California, San Francisco, USA
3Department of Medicine, University of California, San Francisco, USA
4Diabetes Center, University of California, San Francisco, USA
5Department of Biochemistry and Biophysics, University of California, San Francisco, USA
6Chan Zuckerberg Biohub, San Francisco, USA

Tóm tắt

Auto-antibodies (Abs) to type I interferons (IFNs) are found in up to 25% of patients with severe COVID-19, and are implicated in disease pathogenesis. It has remained unknown, however, whether type I IFN auto-Abs are unique to COVID-19, or are also found in other types of severe respiratory illnesses. To address this, we studied a prospective cohort of 284 adults with acute respiratory failure due to causes other than COVID-19. We measured type I IFN auto-Abs by radio ligand binding assay and screened for respiratory viruses using clinical PCR and metagenomic sequencing. Three patients (1.1%) tested positive for type I IFN auto-Abs, and each had a different underlying clinical presentation. Of the 35 patients found to have viral infections, only one patient tested positive for type I IFN auto-Abs. Together, our data suggest that type I IFN auto-Abs are uncommon in critically ill patients with acute respiratory failure due to causes other than COVID-19.

Tài liệu tham khảo

Bastard P, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370:eabd4585. van der Wijst MGP, et al. Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci Transl Med. 2021;13:eabh2624. Bastard P, et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol. 2021;6:eabl4340. Goncalves D. et al. Antibodies against type I interferon: detection and association with severe clinical outcome in COVID‐19 patients. Clin Transl Immunol. 2021;10. Bastard P, et al. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. J Exp Med. 2021;218: e20210554. Langelier C, et al. Integrating host response and unbiased microbe detection for lower respiratory tract infection diagnosis in critically ill adults. Proc Natl Acad Sci USA. 2018. https://doi.org/10.1073/pnas.1809700115. Meager A, et al. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin Exp Immunol. 2003;132:128–36. Wu W, Metcalf JP. The role of type I IFNs in influenza: antiviral superheroes or immunopathogenic villains? J Innate Immun. 2020;12:437–47. Sarma A, et al. Tracheal aspirate RNA sequencing identifies distinct immunological features of COVID-19 ARDS. Nat Commun. 2021;12:5152.